Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
194.13
-1.49 (-0.76%)
At close: Feb 18, 2026, 4:00 PM EST
193.50
-0.63 (-0.32%)
After-hours: Feb 18, 2026, 7:46 PM EST
Biogen Employees
Biogen had 7,500 employees as of December 31, 2025. The number of employees decreased by 105 or -1.38% compared to the previous year.
Employees
7,500
Change (1Y)
-105
Growth (1Y)
-1.38%
Revenue / Employee
$1,318,747
Profits / Employee
$172,387
Market Cap
28.49B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7,500 | -105 | -1.38% |
| Dec 31, 2024 | 7,605 | 35 | 0.46% |
| Dec 31, 2023 | 7,570 | -1,155 | -13.24% |
| Dec 31, 2022 | 8,725 | -885 | -9.21% |
| Dec 31, 2021 | 9,610 | 510 | 5.60% |
| Dec 31, 2020 | 9,100 | 1,700 | 22.97% |
| Dec 31, 2019 | 7,400 | -400 | -5.13% |
| Dec 31, 2018 | 7,800 | 500 | 6.85% |
| Dec 31, 2017 | 7,300 | -100 | -1.35% |
| Dec 31, 2016 | 7,400 | 50 | 0.68% |
| Dec 31, 2015 | 7,350 | -200 | -2.65% |
| Dec 31, 2014 | 7,550 | 700 | 10.22% |
| Dec 31, 2013 | 6,850 | 900 | 15.13% |
| Dec 31, 2012 | 5,950 | 950 | 19.00% |
| Dec 31, 2011 | 5,000 | 150 | 3.09% |
| Dec 31, 2010 | 4,850 | 100 | 2.11% |
| Dec 31, 2009 | 4,750 | 50 | 1.06% |
| Dec 31, 2008 | 4,700 | 400 | 9.30% |
| Dec 31, 2007 | 4,300 | 550 | 14.67% |
| Dec 31, 2006 | 3,750 | 410 | 12.28% |
| Dec 31, 2005 | 3,340 | -926 | -21.71% |
| Dec 31, 2004 | 4,266 | 539 | 14.46% |
| Feb 20, 2004 | 3,727 | 2,732 | 274.57% |
| Jan 31, 2003 | 995 | 303 | 43.79% |
| Jan 31, 2002 | 692 | 199 | 40.37% |
| Jan 31, 2001 | 493 | 86 | 21.13% |
| Jan 31, 2000 | 407 | 42 | 11.51% |
| Jan 31, 1999 | 365 | 26 | 7.67% |
| Dec 31, 1997 | 339 | 71 | 26.49% |
| Dec 31, 1996 | 268 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 92,900 |
| Sanofi | 82,878 |
| Pfizer | 81,000 |
| Novartis AG | 75,267 |
| Merck & Co. | 75,000 |
| Novo Nordisk | 69,505 |
| GSK plc | 68,629 |
| Bristol-Myers Squibb Company | 32,500 |
BIIB News
- 5 days ago - Biogen Inc. (BIIB) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript - Seeking Alpha
- 7 days ago - Biogen Announces Board Chair Transition - GlobeNewsWire
- 9 days ago - Biogen Analysts Boost Their Forecasts After Upbeat Q4 Earnings - Benzinga
- 9 days ago - Biogen FY25 Earnings: Stable EPS, Amid Pressure From The Multiple Sclerosis Franchise - Seeking Alpha
- 12 days ago - Biogen Inc. (BIIB) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Biogen 4Q Revenue Down as Multiple Sclerosis Sales Slide - WSJ
- 12 days ago - Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio. - Barrons
- 12 days ago - Biogen forecasts annual profit above estimates as Leqembi sales pick up - Reuters